Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression

Details for Australian Patent Application No. 2008237929 (hide)

Owner Pangaea Biotech, S.A.

Inventors Taron Roca, Miguel; Rosell Costa, Rafael

Agent Fisher Adams Kelly

Pub. Number AU-A-2008237929

PCT Pub. Number WO2008/125612

Priority 07106177.4 13.04.07 EP

Filing date 11 April 2008

Wipo publication date 23 October 2008

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

5 November 2009 PCT application entered the National Phase

  PCT publication WO2008/125612 Priority application(s): WO2008/125612

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008237930-18F-labelled folates

2008237924-Method for the application of a highstrength coating to workpieces and/or materials